Toxicity of the treatment was limited; grade 3 or higher cytokine release syndrome (CRS) was observed only with the use of GPRC5D-targeted CAR-T, MCARH109, in the clinicaltrials.gov study NCT04555551 and was observed in 1 (6%) patient with r/r MM. Here, GPRC5D is linked to Miyoshi myopathy.